ERBB2 and breast cancer: In the HER2/neu‐inducible breast cancer mouse model, recurrent tumors displayed an EMT signature [68] and an EMT shift has been observed in a portion of lung cancer patient samples that acquired resistance to EGFR inhibitors [69].